TD Cowen raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $25 from $20 and keeps a Buy rating on the shares. The firm notes total product sales beat consensus, with management reporting 19% quarter-to-quarter prescription growth, and GTN remains stable in the 50% range. Near-term growth will be driven by commercial execution and indication expansion. Zoryve life-cycle management and a focused subset of 40-plus possible inflammatory derm indications support mid-term growth, with pipeline and BD fueling long-term gains, TD Cowen adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives
- Arcutis Biotherapeutics price target raised to $22 from $19 at H.C. Wainwright
- Arcutis Biotherapeutics Reports Strong Q2 2025 Growth
- Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating
- Arcutis Biotherapeutics reports Q2 EPS (13c), consensus (16c)